Ibrutinib and Obinutuzumab With or Without Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia
Status: | Recruiting |
---|---|
Conditions: | Blood Cancer, Lymphoma |
Therapuetic Areas: | Oncology |
Healthy: | No |
Age Range: | 18 - 69 |
Updated: | 4/6/2019 |
Start Date: | January 3, 2019 |
End Date: | October 31, 2025 |
A Randomized Phase III Study of the Addition of Venetoclax to Ibrutinib and Obinutuzumab Versus Ibrutinib and Obinutuzumab in Untreated Younger Patients With Chronic Lymphocytic Leukemia (CLL)
This phase III trial studies how well ibrutinib and obinutuzumab with or without venetoclax
work in treating patients with chronic lymphocytic leukemia. Ibrutinib may stop the growth of
cancer cells by blocking some of the enzymes needed for cell growth. Immunotherapy with
monoclonal antibodies, such as obinutuzumab, may help the body's immune system attack the
cancer, and may interfere with the ability of tumor cells to grow and spread. Drugs used in
chemotherapy, such as venetoclax, work in different ways to stop the growth of cancer cells,
either by killing the cells, by stopping them from dividing, or by stopping them from
spreading. Giving ibrutinib, obinutuzumab and venetoclax may work better in treating patients
with chronic lymphocytic leukemia.
work in treating patients with chronic lymphocytic leukemia. Ibrutinib may stop the growth of
cancer cells by blocking some of the enzymes needed for cell growth. Immunotherapy with
monoclonal antibodies, such as obinutuzumab, may help the body's immune system attack the
cancer, and may interfere with the ability of tumor cells to grow and spread. Drugs used in
chemotherapy, such as venetoclax, work in different ways to stop the growth of cancer cells,
either by killing the cells, by stopping them from dividing, or by stopping them from
spreading. Giving ibrutinib, obinutuzumab and venetoclax may work better in treating patients
with chronic lymphocytic leukemia.
PRIMARY OBJECTIVES:
I. To compare the progression free survival (PFS) of the time limited administration of the
three-drug combination ibrutinib-obinutuzumab-venetoclax (IOV) to ibrutinib-obinutuzumab (IO)
in untreated chronic lymphocytic leukemia (CLL) patients younger than 70 years of age.
SECONDARY OBJECTIVES:
I. Evaluate overall survival (OS) of patients based on treatment arm. II. Monitor and assess
toxicity of treatment based on treatment arm.
QUALITY OF LIFE (QOL) OBJECTIVES:
I. To compare quality of life (QOL) in CLL patients during the first 19 cycles of treatment
among patients on each treatment arm.
II. To compare QOL over the long-term in CLL patients receiving continuous therapy using
ibrutinib to that of CLL patients who completed time limited therapy.
III. Evaluate adherence to therapy for the two arms (one of which requires more intense, but
shorter duration treatment, and one of which requires less intense, but indefinite duration
therapy) and explore how adherence in each arm relates to treatment-free survival (TFS).
EXPLORATORY TOBACCO USE OBJECTIVES:
I. To determine the effects of tobacco, operationalized as combustible tobacco (1a), other
forms of tobacco (1b), and environmental tobacco exposure (ETS) (1c) on provider-reported
cancer-treatment toxicity (adverse events [both clinical and hematologic]) and dose
modifications.
II. To determine the effects of tobacco on patient-reported physical symptoms and
psychological symptoms.
III. To examine quitting behaviors and behavioral counseling/support and cessation medication
utilization.
IV. To explore the effect of tobacco use and exposure on treatment duration, relative dose
intensity, and therapeutic benefit.
OUTLINE: Patients are randomized to 1 of 2 arms.
ARM A: Patients receive ibrutinib orally (PO) daily on days 1-28 and obinutuzumab
intravenously (IV) over 4 hours on days 1, 2, 8, and 15 of course 1 and on day 1 of courses
2-6. Patients also receive venetoclax PO once daily (QD) on days 1-28 of courses 3-14.
Treatment repeats every 28 days for up to 19 courses in the absence of disease progression or
unacceptable toxicity.
ARM B: Patients receive ibrutinib PO and obinutuzumab as in arm A. Courses repeat every 28
days in the absence of disease progression or unacceptable toxicity.
All patients, including those who discontinue therapy early, are followed for response until
disease progression, even if non-protocol therapy is initiated. Patients are then followed
every 3 months for first 2 years, every 6 months for years 3-5, and then every 12 months for
years 6-10. All patients must also be followed through completion of all protocol therapy.
I. To compare the progression free survival (PFS) of the time limited administration of the
three-drug combination ibrutinib-obinutuzumab-venetoclax (IOV) to ibrutinib-obinutuzumab (IO)
in untreated chronic lymphocytic leukemia (CLL) patients younger than 70 years of age.
SECONDARY OBJECTIVES:
I. Evaluate overall survival (OS) of patients based on treatment arm. II. Monitor and assess
toxicity of treatment based on treatment arm.
QUALITY OF LIFE (QOL) OBJECTIVES:
I. To compare quality of life (QOL) in CLL patients during the first 19 cycles of treatment
among patients on each treatment arm.
II. To compare QOL over the long-term in CLL patients receiving continuous therapy using
ibrutinib to that of CLL patients who completed time limited therapy.
III. Evaluate adherence to therapy for the two arms (one of which requires more intense, but
shorter duration treatment, and one of which requires less intense, but indefinite duration
therapy) and explore how adherence in each arm relates to treatment-free survival (TFS).
EXPLORATORY TOBACCO USE OBJECTIVES:
I. To determine the effects of tobacco, operationalized as combustible tobacco (1a), other
forms of tobacco (1b), and environmental tobacco exposure (ETS) (1c) on provider-reported
cancer-treatment toxicity (adverse events [both clinical and hematologic]) and dose
modifications.
II. To determine the effects of tobacco on patient-reported physical symptoms and
psychological symptoms.
III. To examine quitting behaviors and behavioral counseling/support and cessation medication
utilization.
IV. To explore the effect of tobacco use and exposure on treatment duration, relative dose
intensity, and therapeutic benefit.
OUTLINE: Patients are randomized to 1 of 2 arms.
ARM A: Patients receive ibrutinib orally (PO) daily on days 1-28 and obinutuzumab
intravenously (IV) over 4 hours on days 1, 2, 8, and 15 of course 1 and on day 1 of courses
2-6. Patients also receive venetoclax PO once daily (QD) on days 1-28 of courses 3-14.
Treatment repeats every 28 days for up to 19 courses in the absence of disease progression or
unacceptable toxicity.
ARM B: Patients receive ibrutinib PO and obinutuzumab as in arm A. Courses repeat every 28
days in the absence of disease progression or unacceptable toxicity.
All patients, including those who discontinue therapy early, are followed for response until
disease progression, even if non-protocol therapy is initiated. Patients are then followed
every 3 months for first 2 years, every 6 months for years 3-5, and then every 12 months for
years 6-10. All patients must also be followed through completion of all protocol therapy.
Inclusion Criteria:
- Diagnosis of CLL according to the National Cancer Institute (NCI)/International
Workshop on Chronic Lymphocytic Leukemia (IWCLL) criteria or small lymphocytic
lymphoma (SLL) according to the World Health Organization (WHO) criteria. This
includes previous documentation of:
- Biopsy-proven small lymphocytic lymphoma OR
- Diagnosis of CLL according to the NCI/IWCLL criteria as evidenced by all of the
following:
- Peripheral blood lymphocyte count of greater than 5 x10^9/L
- Immunophenotype consistent with CLL defined as:
- The predominant population of lymphocytes share both B-cell antigens
(CD19, CD20 [typically dim expression], or CD23) as well as CD5 in the
absence of other pan-T-cell markers (CD3, CD2, etc).
- Clonality as evidenced by kappa or lambda light chain restriction
(typically dim immunoglobulin expression)
- Negative fluorescent in situ hybridization (FISH) analysis for
t(11;14)(IgH/CCND1) on peripheral blood or tissue biopsy (e.g. marrow aspirate)
or negative immunohistochemical stains for cyclin D1 staining on involved tissue
biopsy (e.g. marrow aspirate or lymph node biopsy).
- No prior chemotherapy, BTK inhibitor therapy, venetoclax, small molecule signaling
inhibitor, or monoclonal anti-body therapy for treatment of CLL or SLL
- Has met at least one of the following indications for treatment:
- Evidence of progressive marrow failure as manifested by the development of
worsening anemia (hemoglobin [Hg] < 11 g/dl) and/or thrombocytopenia (platelets <
100 x 10^9/L)
- Symptomatic or progressive lymphadenopathy, splenomegaly, or hepatomegaly
- One or more of the following disease-related symptoms:
- Weight loss >= 10% within the previous 6 months
- Grade 2 or 3 fatigue attributed to CLL
- Fevers > 100.5 degree Fahrenheit (F) for 2 weeks without evidence of
infection
- Clinically significant night sweats without evidence of infection
- Progressive lymphocytosis (not due to the effects of corticosteroids) with an
increase of > 50% over a two-month period or an anticipated doubling time of less
than six months
- Eastern Cooperative Oncology Group (ECOG) performance status between 0-2
- Life expectancy of >= 12 months
- No deletion of 17p13 on cytogenetic analysis by FISH
- Glomerular filtration rate (GFR) > 40 mL/minute as calculated by the Cockcroft-Gault
Formula (obtained =< 14 days prior to registration)
- Total bilirubin =< 1.5 x upper limit of normal (ULN) unless due to Gilbert's disease.
For those with a total bilirubin > 1.5 x ULN, a direct bilirubin should be performed
and must be < 1.5 mg/dL for Gilbert's to be diagnosed (obtained =< 14 days prior to
registration)
- Serum glutamic-oxaloacetic transaminase (SGOT) (aspartate aminotransferase
[AST])/serum glutamate pyruvate transaminase (SGPT) (alanine aminotransferase [ALT])
=< 3.0 x the institutional ULN (obtained =< 14 days prior to registration)
- Prothrombin time (PT)/international normalized ratio (INR) < 1.5 ULN and partial
thromboplastin time (PTT) (activated partial thromboplastin time [aPTT]) < 1.5 x ULN
(obtained =< 14 days prior to registration)
- NOTE: If value is higher due to hepatic involvement by CLL, patient is eligible
- No active hemolytic anemia requiring immunosuppressive therapy or other pharmacologic
treatment. Patients who have a positive Coombs test but no evidence of hemolysis are
NOT excluded from participation
- No current use of corticosteroids. EXCEPTION: Low doses of steroids (< 10 mg of
prednisone or equivalent dose of other steroid) used for treatment of non-hematologic
medical condition (e.g. chronic adrenal insufficiency) is permitted
- No previous autoimmune complications (e.g. autoimmune hemolytic anemia or immune
thrombocytopenia) that have developed since the initial diagnosis of CLL and have
required treatment with high dose corticosteroids (e.g. equivalent of > 20 mg/day of
prednisone), monoclonal antibody based therapy, or chemotherapy. Prior use of
corticosteroids for reasons other than treatment of autoimmune complications is
allowed
- No other active primary malignancy (other than non-melanomatous skin cancer or
carcinoma in situ of the cervix) requiring treatment or limiting expected survival to
=< 2 years
- NOTE: If there is a history of prior malignancy, the patient must not currently
be receiving other specific treatment (other than hormonal therapy for their
cancer)
- Able to adhere to the study visit schedule and other protocol requirements
- No major surgery within 4 weeks (28 days) of first dose of study drug or minor surgery
within 3 days of first dose of study drug
- No radiation therapy =< 4 weeks prior to registration
- Patients who are human immunodeficiency virus positive (HIV+) with undetectable HIV
viral load are eligible provided they meet all other protocol criteria for
participation and are not being treated with protease inhibitors or any non-nucleoside
reverse transcriptase inhibitors (NNRTI) that are CYP3A4 inducers; if being treated
for HIV, patients should be receiving an alternative antiretroviral therapy (ART) that
is not a CYP3A inhibitor
- Patients must not have any of the following conditions:
- Congestive heart failure or New York Heart Association Functional Classification
III or IV congestive heart failure
- History of myocardial infarction, unstable angina, or acute coronary syndrome
within 6 months prior to registration
- Recent infections requiring systemic treatment; need to have completed
anti-biotic therapy > 14 days before the first dose of study drug
- Cerebral vascular accident or intracranial bleed within the last 6 months
- Infection with known chronic, active hepatitis C
- Serologic status reflecting active hepatitis B or C infection. Patients with
hepatitis B or C infection may be eligible if viral loads are undetectable.
Patients may be on suppressive therapy
- Patients are not eligible if they require treatment with a strong cytochrome P450
(CYP) 3A inhibitor
- Patients may not have received the following within 7 days prior to the first dose of
study drug:
- Steroid therapy for anti-neoplastic intent
- Strong and Moderate CYP3A inhibitors
- Strong and Moderate CYP3A inducers
- Patients may not be on any other investigational agents
- Patients may not have received warfarin or another vitamin K antagonist in the
preceding 30 days
- Women must not be pregnant or breast-feeding since this study involves investigational
agents whose genotoxic, mutagenic, and teratogenic effects on the developing fetus and
newborn are unknown. All females of childbearing potential must have a blood test
within 2 weeks prior to registration to rule out pregnancy. A female of childbearing
potential is any woman, regardless of sexual orientation or whether they have
undergone tubal ligation, who meets the following criteria: 1) has not undergone a
hysterectomy or bilateral oophorectomy; or 2) has not been naturally postmenopausal
for at least 24 consecutive months (i.e., has had menses at any time in the preceding
24 consecutive months
- Women of childbearing potential and sexually active males must be strongly advised to
use accepted and highly effective method(s) of contraception or to abstain from sexual
intercourse for the duration of their participation in the study and for:
- 18 months after the last dose of obinutuzumab
- 90 days after the last dose of ibrutinib, and
- 30 days after the last dose of venetoclax Male subjects must also agree to
refrain from sperm donation until 90 days after the last dose of protocol
treatment
- Patient must be able to swallow capsules and not have the following conditions:
- Disease significantly affecting gastrointestinal function
- Resection of the stomach or small bowel
- Symptomatic inflammatory bowel disease
- Ulcerative colitis
- Partial or complete bowel obstruction
- Patient must not be on any other systemic immunosuppressant therapy other than
corticosteroids within 28 days of the first dose of study drug
- Patient must not be vaccinated with live, attenuated vaccines within 4 weeks of first
dose of study drug
- Patient must not have any known bleeding disorders (e.g., von Willebrand's disease) or
hemophilia
- Patient must not have currently active, clinically significant hepatic impairment (>=
moderate hepatic impairment according to the NCI/Child Pugh classification
- Patient must undergo assessment with Timed Up and Go (TUG) test
- Patient must be able to receive xanthine oxidase inhibitor or rasburicase for tumor
lysis syndrome (TLS) prophylaxis
We found this trial at
552
sites
Thornton, Colorado 80260
Principal Investigator: Richard L. Deming
Phone: 308-398-6518
Click here to add this to my saved trials
2545 Schoenersville Rd
Bethlehem, Pennsylvania 18017
Bethlehem, Pennsylvania 18017
(484) 884-2200
Principal Investigator: Tareq Al Baghdadi
Phone: 734-712-3671
Lehigh Valley Hospital - Muhlenberg At Lehigh Valley Health Network, we continually go the extra...
Click here to add this to my saved trials
Bremerton, Washington 98310
Principal Investigator: Richard L. Deming
Phone: 308-398-6518
Click here to add this to my saved trials
666 Elm Street
Buffalo, New York 14263
Buffalo, New York 14263
(716) 845-2300
Principal Investigator: Francisco J. Hernandez-ILizaliturri
Phone: 800-767-9355
Roswell Park Cancer Institute Welcome to Roswell Park Cancer Institute (RPCI), America's first cancer center...
Click here to add this to my saved trials
1200 Pleasant Street
Des Moines, Iowa 50309
Des Moines, Iowa 50309
(515) 241-KIDS
Principal Investigator: Robert J. Behrens
Blank Children's Hospital Blank Children's Hospital is completely dedicated to meeting the unique health care...
Click here to add this to my saved trials
1 Hurley Plaza
Flint, Michigan 48503
Flint, Michigan 48503
(810) 262-9000
Principal Investigator: Tareq Al Baghdadi
Phone: 734-712-3671
Hurley Medical Center From its founding in 1908, Hurley Medical Center has devoted itself to...
Click here to add this to my saved trials
1800 West Charleston Boulevard
Las Vegas, Nevada 89102
Las Vegas, Nevada 89102
(702) 383-2000
Principal Investigator: John A. Ellerton
Phone: 702-384-0013
University Medical Center of Southern Nevada University Medical Center is dedicated to providing the highest...
Click here to add this to my saved trials
4805 Northeast Glisan Street
Portland, Oregon 97213
Portland, Oregon 97213
(503) 215-1111
Principal Investigator: Alison K. Conlin
Phone: 503-215-2614
Providence Portland Medical Center We strive to give those we serve exceptional, compassionate health care...
Click here to add this to my saved trials
3181 Southwest Sam Jackson Park Road
Portland, Oregon 97239
Portland, Oregon 97239
503 494-8311
Principal Investigator: Alexey V. Danilov
Phone: 503-494-1080
Oregon Health and Science University In 1887, the inaugural class of the University of Oregon...
Click here to add this to my saved trials
Seattle, Washington 98104
Principal Investigator: Alison K. Conlin
Phone: 206-215-3086
Click here to add this to my saved trials
Aberdeen, Washington 98520
Principal Investigator: Alison K. Conlin
Phone: 360-412-8958
Click here to add this to my saved trials
Adrian, Michigan 49221
Principal Investigator: Rex B. Mowat
Phone: 517-265-0116
Click here to add this to my saved trials
Allentown, Pennsylvania 18103
Principal Investigator: Tareq Al Baghdadi
Phone: 734-712-3671
Click here to add this to my saved trials
Ames, Iowa 50010
Principal Investigator: Debra M. Prow
Phone: 515-956-4132
Click here to add this to my saved trials
Ames, Iowa 50010
Principal Investigator: Debra M. Prow
Phone: 515-956-4132
Click here to add this to my saved trials
Anaconda, Montana 59711
Principal Investigator: Benjamin T. Marchello
Phone: 406-969-6060
Click here to add this to my saved trials
Anchorage, Alaska 98508
Principal Investigator: Alison K. Conlin
Phone: 907-212-6871
Click here to add this to my saved trials
Anchorage, Alaska 99504
Principal Investigator: Alison K. Conlin
Phone: 907-212-6871
Click here to add this to my saved trials
Anchorage, Alaska 99508
Principal Investigator: Alison K. Conlin
Phone: 907-212-6871
Click here to add this to my saved trials
Anchorage, Alaska 99508
Principal Investigator: Alison K. Conlin
Phone: 907-212-6871
Click here to add this to my saved trials
Click here to add this to my saved trials
Anchorage, Alaska 99508
Principal Investigator: Alison K. Conlin
Phone: 907-212-6871
Click here to add this to my saved trials
Anchorage, Alaska 99508
Principal Investigator: Alison K. Conlin
Phone: 907-212-6871
Click here to add this to my saved trials
Anchorage, Alaska 99508
Principal Investigator: Alison K. Conlin
Phone: 907-212-6871
Click here to add this to my saved trials
5301 McAuley Drive
Ann Arbor, Michigan 48197
Ann Arbor, Michigan 48197
734-712-3456
Principal Investigator: Tareq Al Baghdadi
Phone: 734-712-3671
Saint Joseph Mercy Hospital St. Joseph Mercy Ann Arbor Hospital is a 537-bed teaching hospital...
Click here to add this to my saved trials
921 North Oak Park Boulevard
Arroyo Grande, California 93420
Arroyo Grande, California 93420
Principal Investigator: John A. Ellerton
Phone: 702-384-0013
Click here to add this to my saved trials
Asheville, North Carolina 28801
Principal Investigator: Christopher H. Chay
Phone: 828-213-4150
Click here to add this to my saved trials
Auburn, New York 13021
Principal Investigator: Jeffrey J. Kirshner
Phone: 315-472-7504
Click here to add this to my saved trials
Aurora, Colorado 80012
Principal Investigator: Keren Sturtz
Phone: 303-777-2663
Click here to add this to my saved trials
1501 S Potomac St
Aurora, Colorado 80012
Aurora, Colorado 80012
(303) 695-2600
Principal Investigator: Keren Sturtz
Phone: 303-777-2663
Medical Center of Aurora At The Medical Center of Aurora and Centennial Medical Plaza patients...
Click here to add this to my saved trials
2000 Ogden Ave
Aurora, Illinois 60504
Aurora, Illinois 60504
(630) 978-6200
Principal Investigator: Priyank P. Patel
Phone: 630-978-6212
Rush - Copley Medical Center Rush-Copley is proud to be the leading provider of health...
Click here to add this to my saved trials
3325 Pocahontas Road
Baker City, Oregon 97814
Baker City, Oregon 97814
Principal Investigator: Benjamin T. Marchello
Phone: 734-712-3671
Click here to add this to my saved trials
Ballwin, Missouri 63011
Principal Investigator: Jay W. Carlson
Phone: 314-251-7058
Click here to add this to my saved trials
4305 New Shepherdsville Road
Bardstown, Kentucky 40004
Bardstown, Kentucky 40004
Principal Investigator: Richard L. Deming
Phone: 308-398-6518
Click here to add this to my saved trials
Baton Rouge, Louisiana 70816
Principal Investigator: Carter T. Davis
Phone: 225-761-5346
Click here to add this to my saved trials
Baton Rouge, Louisiana 70836
Principal Investigator: Carter T. Davis
Phone: 504-703-8712
Click here to add this to my saved trials
3535 Pentagon Boulevard
Beavercreek, Ohio 45431
Beavercreek, Ohio 45431
Principal Investigator: Howard M. Gross
Phone: 937-775-1350
Click here to add this to my saved trials
Bellingham, Washington 98225
Principal Investigator: Alison K. Conlin
Phone: 360-715-4133
Click here to add this to my saved trials
800 Farson Street
Belpre, Ohio 45714
Belpre, Ohio 45714
(740) 401-0417
Principal Investigator: Timothy D. Moore
Phone: 800-523-3977
Strecker Cancer Center-Belpre The Memorial Health System's Strecker Cancer Center, Belpre combines the clinical expertise...
Click here to add this to my saved trials
Bemidji, Minnesota 56601
Principal Investigator: Preston D. Steen
Phone: 218-333-5000
Click here to add this to my saved trials
Bend, Oregon 97701
Principal Investigator: Alison K. Conlin
Phone: 541-706-2909
Click here to add this to my saved trials
Billings, Montana 59102
Principal Investigator: Keren Sturtz
Phone: 800-648-6274
Click here to add this to my saved trials
1233 North 30th Street
Billings, Montana 59101
Billings, Montana 59101
406-237-7000
Principal Investigator: Keren Sturtz
Phone: 406-969-6060
Saint Vincent Healthcare The Sisters of Charity of Leavenworth, Kansas, founded St. Vincent Healthcare in...
Click here to add this to my saved trials
Billings, Montana 59101
Principal Investigator: Benjamin T. Marchello
Phone: 800-996-2663
Click here to add this to my saved trials
Birmingham, Alabama 35233
Principal Investigator: Amitkumar N. Mehta
Phone: 205-934-0220
Click here to add this to my saved trials
300 N. Seventh St.
Bismarck, North Dakota 58501
Bismarck, North Dakota 58501
(701) 323-6000
Principal Investigator: Preston D. Steen
Phone: 701-323-5760
Sanford Bismarck Medical Center Whether your stay in our hospital is one day for same...
Click here to add this to my saved trials
1505 Eastland Drive
Bloomington, Illinois 61701
Bloomington, Illinois 61701
309-662-2102
Principal Investigator: Bryan A. Faller
Phone: 309-243-3605
Illinois CancerCare-Bloomington Illinois CancerCare, P.C. is a comprehensive practice treating patients withcancer andblood diseases. Our...
Click here to add this to my saved trials
Boardman, Ohio 44512
Principal Investigator: Howard M. Gross
Phone: 330-629-7500
Click here to add this to my saved trials
Boise, Idaho 83706
Principal Investigator: Benjamin T. Marchello
Phone: 734-712-3671
Click here to add this to my saved trials
100 E Idaho St
Boise, Idaho 83712
Boise, Idaho 83712
(208) 381-2711
Principal Investigator: Alison K. Conlin
Saint Luke's Mountain States Tumor Institute For more than 100 years, St. Luke
Click here to add this to my saved trials
Bonne Terre, Missouri 63628
Principal Investigator: Bryan A. Faller
Phone: 314-996-5569
Click here to add this to my saved trials
Boone, Iowa 50036
Principal Investigator: Debra M. Prow
Phone: 515-956-4132
Click here to add this to my saved trials
1100 Balsam Ave
Boulder, Colorado 80304
Boulder, Colorado 80304
(303) 440-2273
Principal Investigator: Keren Sturtz
Phone: 303-777-2663
Boulder Community Hospital Founded in 1922 as a community-owned and operated not-for-profit hospital, Boulder Community...
Click here to add this to my saved trials
Boulder, Colorado 80303
Principal Investigator: Keren Sturtz
Phone: 303-777-2663
Click here to add this to my saved trials
915 Highland Blvd
Bozeman, Montana 59715
Bozeman, Montana 59715
(406) 414-5000
Principal Investigator: Benjamin T. Marchello
Phone: 406-969-6060
Bozeman Deaconess Hospital Bozeman Deaconess Hospital is a Joint Commission certified, licensed Level III trauma...
Click here to add this to my saved trials
Branson, Missouri 65616
Principal Investigator: Jay W. Carlson
Phone: 417-269-4520
Click here to add this to my saved trials
Bremerton, Washington 98310
Principal Investigator: Richard L. Deming
Phone: 308-398-6518
Click here to add this to my saved trials
7575 Grand River Avenue
Brighton, Michigan 48114
Brighton, Michigan 48114
Principal Investigator: Tareq Al Baghdadi
Phone: 734-712-3671
Click here to add this to my saved trials
7575 Grand River Avenue
Brighton, Michigan 48114
Brighton, Michigan 48114
Principal Investigator: Tareq Al Baghdadi
Phone: 734-712-3671
Click here to add this to my saved trials
Bryan, Texas 77802
Principal Investigator: Richard L. Deming
Phone: 308-398-6518
Click here to add this to my saved trials
130 S Bryn Mawr Ave
Bryn Mawr, Pennsylvania 19010
Bryn Mawr, Pennsylvania 19010
(484) 337-3000
Principal Investigator: Albert S. DeNittis
Phone: 484-476-2649
Bryn Mawr Hospital Bryn Mawr Hospital, a nationally recognized community teaching hospital, is conveniently located...
Click here to add this to my saved trials
Burbank, California
Principal Investigator: Alison K. Conlin
Phone: 818-847-4793
Click here to add this to my saved trials
Burien, Washington 98166
Principal Investigator: Richard L. Deming
Phone: 308-398-6518
Click here to add this to my saved trials
Burlington, Wisconsin 53105
Principal Investigator: Shamsuddin Virani
Phone: 414-302-2304
Click here to add this to my saved trials
201 E Nicollet Blvd
Burnsville, Minnesota 55337
Burnsville, Minnesota 55337
(952) 892-2000
Principal Investigator: David M. King
Phone: 952-993-1517
Fairview Ridges Hospital Fairview Ridges Hospital is a 150-bed, Level III Trauma Care facility, offering...
Click here to add this to my saved trials
400 South Clark Street
Butte, Montana 59701
Butte, Montana 59701
406-723-2500
Principal Investigator: Keren Sturtz
Phone: 406-723-2621
Saint James Community Hospital and Cancer Treatment Center St. James Healthcare has played an important...
Click here to add this to my saved trials
3123 Medical Dr
Caldwell, Idaho 83605
Caldwell, Idaho 83605
Principal Investigator: Benjamin T. Marchello
Phone: 734-712-3671
Click here to add this to my saved trials
210 W Walnut St
Canton, Illinois 61520
Canton, Illinois 61520
309-647-5240
Principal Investigator: Bryan A. Faller
Phone: 309-243-3605
Illinois CancerCare - Canton Illinois CancerCare is one of the largest private oncology and hematology...
Click here to add this to my saved trials
1600 South Canton Center Road
Canton, Michigan 48188
Canton, Michigan 48188
Principal Investigator: Tareq Al Baghdadi
Phone: 734-712-3671
Click here to add this to my saved trials
1600 South Canton Center Road
Canton, Michigan 48188
Canton, Michigan 48188
Principal Investigator: Tareq Al Baghdadi
Phone: 734-712-3671
Click here to add this to my saved trials
211 Saint Francis Drive
Cape Girardeau, Missouri 63703
Cape Girardeau, Missouri 63703
573-331-3000
Principal Investigator: Bryan A. Faller
Phone: 573-334-2230
Saint Francis Medical Center Saint Francis Medical Center is a 282-bed facility serving more than...
Click here to add this to my saved trials
789 Mt Auburn Rd
Cape Girardeau, Missouri 63703
Cape Girardeau, Missouri 63703
(573) 519-4725
Principal Investigator: Bryan A. Faller
Phone: 573-651-5550
Southeast Cancer Center SoutheastHEALTH is a far-reaching network of providers and facilities including Southeast Hospital...
Click here to add this to my saved trials
Carbondale, Illinois 62902
Principal Investigator: Bryan A. Faller
Phone: 618-457-5200
Click here to add this to my saved trials
401 North Hooper Street
Caro, Michigan 48723
Caro, Michigan 48723
Principal Investigator: Tareq Al Baghdadi
Phone: 734-712-3671
Click here to add this to my saved trials
Carson City, Nevada 89703
Principal Investigator: John A. Ellerton
Phone: 702-384-0013
Click here to add this to my saved trials
Carterville, Illinois 62918
Principal Investigator: Bryan A. Faller
Phone: 618-985-3333
Click here to add this to my saved trials
160 S Adams St
Carthage, Illinois 62321
Carthage, Illinois 62321
(217) 357-6877
Principal Investigator: Bryan A. Faller
Phone: 309-243-3605
Illinois CancerCare - Carthage Illinois CancerCare, P.C. is a comprehensive practice treating patients withcancer andblood...
Click here to add this to my saved trials
Cary, North Carolina 27511
Principal Investigator: Michael C. Marte
Phone: 919-233-8585
Click here to add this to my saved trials
Centerville, Ohio 45459
Principal Investigator: Howard M. Gross
Phone: 937-775-1350
Click here to add this to my saved trials
Centerville, Ohio 45459
Principal Investigator: Howard M. Gross
Phone: 937-775-1350
Click here to add this to my saved trials
Centralia, Illinois 62801
Principal Investigator: Bryan A. Faller
Phone: 217-876-4740
Click here to add this to my saved trials
Centralia, Washington 98531
Principal Investigator: Alison K. Conlin
Phone: 360-412-8958
Click here to add this to my saved trials
Chadds Ford, Pennsylvania 19317
Principal Investigator: Gregory A. Masters
Phone: 302-623-4450
Click here to add this to my saved trials
Click here to add this to my saved trials
14650 East Old US Highway 12
Chelsea, Michigan 48118
Chelsea, Michigan 48118
Principal Investigator: Tareq Al Baghdadi
Phone: 734-712-3671
Click here to add this to my saved trials
775 South Main Street
Chelsea, Michigan 48118
Chelsea, Michigan 48118
Principal Investigator: Tareq Al Baghdadi
Phone: 734-712-3671
Click here to add this to my saved trials
Cheyenne, Wyoming 82001
Principal Investigator: Keren Sturtz
Phone: 303-777-2663
Click here to add this to my saved trials
1653 W. Congress Parkway
Chicago, Illinois 60612
Chicago, Illinois 60612
(312) 942-5000
Principal Investigator: Seo-Hyun Kim
Phone: 312-942-5498
Rush University Medical Center Rush University Medical Center encompasses a 664-bed hospital serving adults and...
Click here to add this to my saved trials
272 Hospital Rd
Chillicothe, Ohio 45601
Chillicothe, Ohio 45601
740-779-7500
Principal Investigator: Timothy D. Moore
Phone: 877-779-7585
Adena Regional Medical Center Since 1895, Adena Health System has remained focused on its commitment...
Click here to add this to my saved trials
Cincinnati, Ohio 45220
Principal Investigator: Richard L. Deming
Phone: 308-398-6518
Click here to add this to my saved trials
Cincinnati, Ohio 45242
Principal Investigator: Richard L. Deming
Phone: 308-398-6518
Click here to add this to my saved trials
Cincinnati, Ohio 45247
Principal Investigator: Richard L. Deming
Phone: 308-398-6518
Click here to add this to my saved trials
Cincinnati, Ohio 45255
Principal Investigator: Richard L. Deming
Phone: 308-398-6518
Click here to add this to my saved trials
Cincinnati, Ohio 45236
Principal Investigator: Howard M. Gross
Phone: 937-775-1350
Click here to add this to my saved trials
Clackamas, Oregon 97015
Principal Investigator: Alison K. Conlin
Phone: 503-215-2614
Click here to add this to my saved trials
9280 SE Sunnybrook Blvd #100
Clackamas, Oregon 97015
Clackamas, Oregon 97015
(503) 513-3300
Principal Investigator: Alison K. Conlin
Phone: 503-215-2614
Clackamas Radiation Oncology Center State-of-the-art technology and compassionate care come together at Clackamas Radiation Oncology...
Click here to add this to my saved trials
5680 Bow Pointe Drive
Clarkston, Michigan 48346
Clarkston, Michigan 48346
Principal Investigator: Tareq Al Baghdadi
Phone: 734-712-3671
Click here to add this to my saved trials
31500 Telegraph Road
Clarkston, Michigan 48346
Clarkston, Michigan 48346
Principal Investigator: Tareq Al Baghdadi
Phone: 734-712-3671
Click here to add this to my saved trials
Clinton, North Carolina 28328
Principal Investigator: Nagesh H. Jayaram
Phone: 919-587-9077
Click here to add this to my saved trials
Clive, Iowa 50325
Principal Investigator: Richard L. Deming
Phone: 308-398-6518
Click here to add this to my saved trials
12495 University Ave
Clive, Iowa 50325
Clive, Iowa 50325
(515) 358-9700
Principal Investigator: Richard L. Deming
Phone: 308-398-6518
Mercy Cancer Center - West Lakes When it comes to cancer care, there
Click here to add this to my saved trials